| [1] |
Adams P C, Jeffrey G, Ryan J. Haemochromatosis[J]. Lancet, 2023, 401( 10390): 1811- 1821. DOI: 10.1016/S0140-6736(23)00287-8.
|
| [2] |
Camaschella C, Poggiali E. Rare types of genetic hemochromatosis[J]. Acta Haematol, 2009, 122( 2-3): 140- 145. DOI: 10.1159/000243798.
|
| [3] |
Kowdley K V, Brown K E, Ahn J, et al. ACG clinical guideline: Hereditary hemochromatosis[J]. Am J Gastroenterol, 2019, 114( 8): 1202- 1218. DOI: 10.14309/ajg.0000000000000315.
|
| [4] |
Zhang W, Xu A J, Li Y M, et al. A novel SLC40A1 p.Y333H mutation with gain of function of ferroportin: A recurrent cause of haemochromatosis in China[J]. Liver Int, 2019, 39( 6): 1120- 1127. DOI: 10.1111/liv.14013.
|
| [5] |
Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of hereditary hemochromatosis[J]. Chin J Hepatol, 2024, 32( 9): 787- 798. DOI: 10.3760/cma.j.cn501113-20240712-00319.
中华医学会肝病学分会. 中国遗传性血色病诊疗指南[J]. 中华肝脏病杂志, 2024, 32( 9): 787- 798. DOI: 10.3760/cma.j.cn501113-20240712-00319.
|
| [6] |
Hao Kunyan, Wang Yong, Yu Yuecheng. An excerpt of the EASL clinical practice guidelines on haemochromatosis[J]. J Clin Hepatol, 2022, 38( 9): 1999- 2004. DOI: 10.3969/j.issn.1001-5256.2022.09.011.
郝坤艳, 汪勇, 于乐成.《2022年欧洲肝病学会血色病临床实践指南》摘译[J]. 临床肝胆病杂志, 2022, 38( 9): 1999- 2004. DOI: 10.3969/j.issn.1001-5256.2022.09.011.
|
| [7] |
Lv T X, Zhang W, Xu A J, et al. Non-HFE mutations in haemochromatosis in China: Combination of heterozygous mutations involving HJV signal peptide variants[J]. J Med Genet, 2018, 55( 10): 650- 660. DOI: 10.1136/jmedgenet-2018-105348.
|
| [8] |
Mayr R, Janecke A R, Schranz M, et al. Ferroportin disease: A systematic meta-analysis of clinical and molecular findings[J]. J Hepatol, 2010, 53( 5): 941- 949. DOI: 10.1016/j.jhep.2010.05.016.
|
| [9] |
Zhu Chengyu, Chen Qi, Feng Zhongxin. Hereditary hemochromatosis caused by mutation in the SLC40 A1 gene: A case report[J]. J Clin Hepatol, 2021, 37( 5): 1180- 1182. DOI: 10.3969/j.issn.1001-5256.2021.05.041.
朱承谕, 陈琦, 封忠昕. SLC40 A1基因突变致遗传性血色病1例报告[J]. 临床肝胆病杂志, 2021, 37( 5): 1180- 1182. DOI: 10.3969/j.issn.1001-5256.2021.05.041.
|
| [10] |
Girelli D, Busti F, Brissot P, et al. Hemochromatosis classification: Update and recommendations by the BIOIRON Society[J]. Blood, 2022, 139( 20): 3018- 3029. DOI: 10.1182/blood.2021011338.
|
| [11] |
Uguen K, Ka C, Collod-Béroud G, et al. The spectra of disease-causing mutations in the ferroportin 1(SLC40A1) encoding gene and related iron overload phenotypes(hemochromatosis type 4 and ferroportin disease)[J]. Hum Mutat, 2023, 2023: 5162256. DOI: 10.1155/2023/5162256.
|
| [12] |
Czaja A J. Review article: Iron disturbances in chronic liver diseases other than haemochromatosis- pathogenic, prognostic, and therapeutic implications[J]. Aliment Pharmacol Ther, 2019, 49( 6): 681- 701. DOI: 10.1111/apt.15173.
|
| [13] |
Li Guangming, Fan Jiangao. Research progress in role of iron overload in non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2013, 29( 12): 897- 900. DOI: 10.3969/j.issn.1001-5256.2013.12.006.
李光明, 范建高. 铁超载在非酒精性脂肪性肝病中的作用[J]. 临床肝胆病杂志, 2013, 29( 12): 897- 900. DOI: 10.3969/j.issn.1001-5256.2013.12.006.
|
| [14] |
Pietrangelo A. Ferroportin disease: Pathogenesis, diagnosis and treatment[J]. Haematologica, 2017, 102( 12): 1972- 1984. DOI: 10.3324/haematol.2017.170720.
|